ScholarIQanswers from OpenAlex & ORCID
Mario Campone
ResearcherPublications, citations & collaboration network
Mario Campone is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mario Campone have?
ScholarIQindexed works
Mario Campone has 1,090 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mario Campone have?
ScholarIQcitation count
Mario Campone has 53,975 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mario Campone?
ScholarIQh-index
Mario Campone has an h-index of 94 in OpenAlex.
What is the i10-index of Mario Campone?
ScholarIQi10-index
Mario Campone has an i10-index of 394 in OpenAlex.
What is the ORCID of Mario Campone?
ScholarIQorcid
The ORCID for Mario Campone is on the source record.
What is the OpenAlex record for Mario Campone?
ScholarIQopenalex
The OpenAlex for Mario Campone is on the source record.
What are the most-cited papers on Mario Campone?
ScholarIQmost cited works
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain, David Miles, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im, Semiglazov Vf, Eva Ciruelos, Andreas Schneeweiß, Sherene Loi, Estefanía Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark Benyunes, Javier Cortés, Richy Agajanian, Rizvana Ahmad, Bahriye Aktas, Victor Hugo Medeiros Alencar, Dino Amadori, Jurandyr Moreira de Andrade, Fábio Franke, Catia Angiolini, Kenjiro Aogi, Jess F. Armor, Wichit Arpornwirat, L. Assersohn, William Audeh, Walter E. Aulitzky, Sérgio Jobim Azevedo, Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, H. A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Katarína Petráková, Kim T. Blackwell, Eric P. Winer, W Janni, S. Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, S. Mondal, Faye Su, Marshall G. Miller, Mohamed Elmeliegy, Caroline Germa, Joyce O’Shaughnessy
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent, Alba A. Brandes, R. Rampling, Mathilde C.M. Kouwenhoven, Johan M. Kros, Alain Carpentier, Paul M. Clément, M. Frénay, Mario Campone, Jean‐François Baurain, Jean-Paul Armand, Martin Taphoorn, Alicia Tosoni, Heidemarie Kletzl, Barbara Klughammer, Denis Lacombe, Thierry Gorlia
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Hervé Bonnefoi, Guy Jérusalem, Rupert Bartsch, Manuela Rabaglio, Roswitha Kammler, Rudolf Maibach, Mark J. Smyth, Angelo Di Leo, Marco Colleoni, Giuseppe Viale, Meredith M. Regan, Fabrice André, Debora Fumagalli, Richard D. Gelber, Theodora Goulioti, Anita Hiltbrunner, Rita L. Hui, Heidi Roschitzki, Barbara Ruepp, Frances M. Boyle, Rolf A. Stahel, Stefan Aebi, Alan S. Coates, Aron Goldhirsch, Per Karlsson, Ingrid Kössler, Stamatina Fournarakou, Adriana Gasca, Rita Pfister, Sabrina Ribeli-Hofmann, Magdelena Weber, Daniela Celotto, Carmen Comune, M. Frapolli, Magdalena Sánchez-Hohl, Hui Huang, Caitlin Mahoney, Karen N. Price, Karolyn Scott, Holly Shaw, Susan M. Fischer, Mónica Greco, Colleen King, Stefania Andrighetto, Martine Piccart, Heather E. Findlay, Michelle Jenkins, Vassiliki Karantza, Jaime Mejia, Patrick Schneier